Geneoscopy and Labcorp have entered into a multi-year agreement to distribute a noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test. This test, currently under review by the US Food and Drug Administration (FDA) through a premarket approval application (PMA), is designed to detect colorectal cancer and precancerous lesions. The test’s effectiveness was demonstrated in the pivotal CRC-PREVENT study, which showed high sensitivity for colorectal cancer (CRC) and advanced adenomas, particularly in younger participants aged between 45 and 49 years.
Vince Wong, Geneoscopy’s chief commercial officer, emphasized the significance of the collaboration with Labcorp, noting its potential to expand patient and clinician access to this noninvasive screening test. The partnership aims to reduce barriers to screening and address health inequities. Upon FDA approval, Labcorp will offer the test, conducted by Geneoscopy, as part of its screening programs, making it easily accessible to healthcare customers.
Dr. Brian Caveney, Labcorp’s chief medical and scientific officer, highlighted the test’s sensitivity and its role as an innovative, accessible, and reliable option for colorectal cancer detection nationwide.